Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in its key drugs Ozempic and Wegovy, in a deal that some analysts said sounded less onerous than feared.

Even after Trump’s new deal, obesity drugs are still too expensive.

Novo Nordisk lowered its guidance in part due to disappointing demand for Ozempic. Key Takeaways. Novo Nordisk cut its outlook as it sees

Danish company is battling with Pfizer for US biotech as they seek edge in growing market for weight-loss drugs

Gordon Findlay of Novo Nordisk collapsed in the Oval Office Thursday afternoon as President Trump announced a plan to reduce the price of weight-loss drugs, including Ozempic. Findlay was helped to his feet,

The ultimate defense in our industry is in innovation,” Karsten Munk Knudsen told Fortune in an exclusive interview.

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) to set a negotiated price for